Tizania Life Science Plc is a UK-based clinical stage biotechnology company that is engaged in the discovery and development of molecules and related diagnostics to treat diseases in immunology and oncology. It is specialised in the developing therapies for autoimmune and inflammatory disease, degenerative diseases and cancer related to the liver. Its objective is to bring breakthrough therapies to treat COVID-19, Crohn’s Disease and Heapatocellular Carcinoma and Progressive Multiple Sclerosis. The company is listed on the London Stock Exchange as LON: TILS and in Nasdaq as NASDAQ: TLSA.
The company focuses include COVID-19, Crohn’s Disease, Hepatocellular Cancer and Progressive Multiple Sclerosis. The company’s products include Foralumab (TZLS-401), Anti IL-6R (TZLS-501) and Milciclib (TZLS-201). The company’s Foralumab (TZLS-401) product is the first and only, fully human anti-CD3 antibody around the world, which can be delivered orally for the treatment of Crohn’s Disease and other autoimmune diseases through reduced toxicity and high efficacy. The United State Patent and Trademark Office permitted a patent covering its proprietary formulation for oral administration.
The company, by delivering Foralumab through nasal administration, is treating patients with neurodegenerative diseases such as progressive MS (pro-MS). It has anticipates the initiation of a Phase 2 trial in Q2 2021, with nasally administered Foralumab in progressive multiple scleroses (pro-MS) and with orally administered Foralumab for Crohn’s indication is anticipated to be initiated shortly. The company is accelerating development and cGMP manufacturing of Anti-IL-6r monoclonal antibody for treatment of COVID-19 and other autoimmune disease. The company aims to complete the development of inhalation technology to offer stable aerosols of TZLS-501and other antiviral drugs. The Milciclib (TZLS-201) is an orally bioavailable, broad spectrum inhibitor of cyclin-dependent kinases, small molecule or CDKs and Src family kinases.
The company has recently submitted a patent application on potential use of Foralumab, which covers invention related to improving CAR-T expansion and/ or survival, to improve success of chimeric antigen receptor T cells (CAR-T) therapy. In May 2020, the company announced the spin out of SPARE and StemPrintER into a separate company.
3rd Floor, 11-12 St James's Square, London, SW1Y 4LB, United Kingdom